BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 18421047)

  • 1. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia.
    Yang L; Panetta JC; Cai X; Yang W; Pei D; Cheng C; Kornegay N; Pui CH; Relling MV
    J Clin Oncol; 2008 Apr; 26(12):1932-9. PubMed ID: 18421047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
    Pession A; Valsecchi MG; Masera G; Kamps WA; Magyarosy E; Rizzari C; van Wering ER; Lo Nigro L; van der Does A; Locatelli F; Basso G; Aricò M
    J Clin Oncol; 2005 Oct; 23(28):7161-7. PubMed ID: 16192600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia.
    Appel IM; Hop WC; van Kessel-Bakvis C; Stigter R; Pieters R
    Thromb Haemost; 2008 Aug; 100(2):330-7. PubMed ID: 18690355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.
    Hijiya N; Stewart CF; Zhou Y; Campana D; Coustan-Smith E; Rivera GK; Relling MV; Pui CH; Gajjar A
    Cancer; 2008 May; 112(9):1983-91. PubMed ID: 18318429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia.
    Kawedia JD; Liu C; Pei D; Cheng C; Fernandez CA; Howard SC; Campana D; Panetta JC; Bowman WP; Evans WE; Pui CH; Relling MV
    Blood; 2012 Feb; 119(7):1658-64. PubMed ID: 22117041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-asparaginase as a marker of chemotherapy dose modification in children with acute lymphoblastic leukemia.
    Baillargeon J; Langevin AM; Lewis M; Thomas PJ; Mullins J; Dugan J; Pollock BH
    Cancer; 2005 Dec; 104(12):2858-61. PubMed ID: 16288492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between high vascular endothelial growth factor-A serum levels and treatment outcome in patients with standard-risk acute lymphoblastic leukemia: a report from Children's Oncology Group Study CCG-1962.
    Avramis IA; Panosyan EH; Dorey F; Holcenberg JS; Avramis VI;
    Clin Cancer Res; 2006 Dec; 12(23):6978-84. PubMed ID: 17145817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [L-asparaginase-induced hyperlipidemia in a case of acute lymphoblastic leukemia].
    Konya H; Tamura S; Miyazaki E; Inoue N; Okamoto T; Takemoto Y; Kohsaki M; Kanemaru A; Kakishita E
    Rinsho Ketsueki; 1991 Mar; 32(3):250-4. PubMed ID: 2041167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of anti-asparaginase antibodies in childhood acute lymphoblastic leukemia.
    Zalewska-Szewczyk B; Andrzejewski W; Bodalski J
    Pediatr Blood Cancer; 2004 Oct; 43(5):600-2. PubMed ID: 15382279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia.
    Cohen H; Bielorai B; Harats D; Toren A; Pinhas-Hamiel O
    Pediatr Blood Cancer; 2010 May; 54(5):703-6. PubMed ID: 20063421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Research on the pharmacokinetics and pharmacodynamics of L-asparaginase during its treatment of childhood acute lymphoblastic leukemia].
    Chen FX; Cui YQ; Wu ZL; Ye TZ; Lai YH; Zou YW; Lu CY; Guan JM; Wei FG; Zhang H
    Zhonghua Xue Ye Xue Za Zhi; 2005 Feb; 26(2):100-2. PubMed ID: 15921627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study.
    Klug Albertsen B; Schmiegelow K; Schrøder H; Carlsen NT; Rosthøj S; Avramis VI; Jakobsen P
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):117-20. PubMed ID: 12172975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
    Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
    Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study.
    Hunault-Berger M; Chevallier P; Delain M; Bulabois CE; Bologna S; Bernard M; Lafon I; Cornillon J; Maakaroun A; Tizon A; Padrazzi B; Ifrah N; Gruel Y;
    Haematologica; 2008 Oct; 93(10):1488-94. PubMed ID: 18728028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. All dex'ed out with nowhere to go?
    Adamson PC; Barrett JS
    J Clin Oncol; 2008 Apr; 26(12):1917-8. PubMed ID: 18421043
    [No Abstract]   [Full Text] [Related]  

  • 16. Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemia.
    Evans WE; Rodman JH; Relling MV; Petros WP; Stewart CF; Pui CH; Rivera GK
    J Pharmacol Exp Ther; 1992 Jan; 260(1):71-7. PubMed ID: 1731053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia.
    Meister B; Kropshofer G; Klein-Franke A; Strasak AM; Hager J; Streif W
    Pediatr Blood Cancer; 2008 Feb; 50(2):298-303. PubMed ID: 17443678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.
    Rizzari C; Citterio M; Zucchetti M; Conter V; Chiesa R; Colombini A; Malguzzi S; Silvestri D; D'Incalci M
    Haematologica; 2006 Jan; 91(1):24-31. PubMed ID: 16434367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood lipid profiles in children with acute lymphoblastic leukemia.
    Halton JM; Nazir DJ; McQueen MJ; Barr RD
    Cancer; 1998 Jul; 83(2):379-84. PubMed ID: 9669823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.
    Manabe A; Ohara A; Hasegawa D; Koh K; Saito T; Kiyokawa N; Kikuchi A; Takahashi H; Ikuta K; Hayashi Y; Hanada R; Tsuchida M;
    Haematologica; 2008 Aug; 93(8):1155-60. PubMed ID: 18519521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.